"Revolutionary Drug Halts Aggressive Breast Cancer Growth"

Scientists in Australia have developed a new oral drug, CDDD11-8, which shows promise in halting the growth of aggressive triple-negative breast cancer by selectively inhibiting the CDK9 pathway that cancerous cells rely on for survival and growth. Unlike chemotherapy, this drug targets only cancerous cells within breast tissue and metastatic lesions, showing potential for improved survival rates without toxic side effects on healthy cells. The drug has demonstrated success in animal models and patient-derived breast cancer tissue, offering hope for a new targeted treatment option for this deadly form of breast cancer.